152 related articles for article (PubMed ID: 21682818)
1. Pharmacokinetics and ex vivo whole blood clot formation of a new recombinant FVIII (N8) in haemophilia A dogs.
Karpf DM; Kjalke M; Thim L; Agersø H; Merricks EP; Defriess N; Nichols TC; Ezban M
Haemophilia; 2011 Sep; 17(5):e963-8. PubMed ID: 21682818
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of a new recombinant FVIII (N8) in haemophilia A mice.
Elm T; Karpf DM; Øvlisen K; Pelzer H; Ezban M; Kjalke M; Tranholm M
Haemophilia; 2012 Jan; 18(1):139-45. PubMed ID: 21771205
[TBL] [Abstract][Full Text] [Related]
3. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
[TBL] [Abstract][Full Text] [Related]
4. Functional characteristics of N8, a new recombinant FVIII.
Christiansen ML; Balling KW; Persson E; Hilden I; Bagger-Sørensen A; Sørensen BB; Viuff D; Segel S; Klausen NK; Ezban M; Lethagen S; Steenstrup TD; Kjalke M
Haemophilia; 2010 Nov; 16(6):878-87. PubMed ID: 20546031
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
[TBL] [Abstract][Full Text] [Related]
6. International comparative field study of N8 evaluating factor VIII assay performance.
Viuff D; Barrowcliffe T; Saugstrup T; Ezban M; Lillicrap D
Haemophilia; 2011 Jul; 17(4):695-702. PubMed ID: 21426445
[TBL] [Abstract][Full Text] [Related]
7. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.
Rode F; Almholt K; Petersen M; Kreilgaard M; Kjalke M; Karpf DM; Groth AV; Johansen PB; Larsen LF; Loftager M; Haaning J
J Thromb Haemost; 2018 Jun; 16(6):1141-1152. PubMed ID: 29582559
[TBL] [Abstract][Full Text] [Related]
8. A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate(®)).
Pastoft AE; Lykkesfeldt J; Ezban M; Tranholm M; Whinna HC; Lauritzen B
Haemophilia; 2012 Sep; 18(5):782-8. PubMed ID: 22500820
[TBL] [Abstract][Full Text] [Related]
9. Preclinical efficacy and safety of rVIII-SingleChain (CSL627), a novel recombinant single-chain factor VIII.
Zollner SB; Raquet E; Müller-Cohrs J; Metzner HJ; Weimer T; Pragst I; Dickneite G; Schulte S
Thromb Res; 2013 Aug; 132(2):280-7. PubMed ID: 23830969
[TBL] [Abstract][Full Text] [Related]
10. Turoctocog alfa (NovoEight®)--from design to clinical proof of concept.
Ezban M; Vad K; Kjalke M
Eur J Haematol; 2014 Nov; 93(5):369-76. PubMed ID: 24797664
[TBL] [Abstract][Full Text] [Related]
11. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A.
Di Paola J; Smith MP; Klamroth R; Mannucci PM; Kollmer C; Feingold J; Kessler C; Pollmann H; Morfini M; Udata C; Rothschild C; Hermans C; Janco R
Haemophilia; 2007 Mar; 13(2):124-30. PubMed ID: 17286764
[TBL] [Abstract][Full Text] [Related]
12. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight®), in patients with hemophilia A.
Jiménez-Yuste V; Lejniece S; Klamroth R; Suzuki T; Santagostino E; Karim FA; Saugstrup T; Møss J
J Thromb Haemost; 2015 Mar; 13(3):370-9. PubMed ID: 25495795
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Meunier S; Alamelu J; Ehrenforth S; Hanabusa H; Abdul Karim F; Kavakli K; Khodaie M; Staber J; Stasyshyn O; Yee DL; Rageliene L
Thromb Haemost; 2017 Aug; 117(9):1705-1713. PubMed ID: 28692108
[TBL] [Abstract][Full Text] [Related]
14. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
Tiede A; Brand B; Fischer R; Kavakli K; Lentz SR; Matsushita T; Rea C; Knobe K; Viuff D
J Thromb Haemost; 2013 Apr; 11(4):670-8. PubMed ID: 23398640
[TBL] [Abstract][Full Text] [Related]
15. Platelet-dependent coagulation assays for factor VIII efficacy measurement after substitution therapy in patients with haemophilia A.
Bassus S; Wegert W; Krause M; Escuriola-Ettinghausen C; Siegemund A; Petros S; Scholz T; Scharrer I; Kreuz W; Engelmann L; Kirchmaier CM
Platelets; 2006 Sep; 17(6):378-84. PubMed ID: 16973498
[TBL] [Abstract][Full Text] [Related]
16. Monitoring rFVIII prophylaxis dosing using global haemostasis assays.
Al Hawaj MA; Martin EJ; Venitz J; Barrett JC; Kuhn JG; Nolte ME; Brophy DF
Haemophilia; 2013 May; 19(3):409-14. PubMed ID: 23510278
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Giangrande P; Andreeva T; Chowdary P; Ehrenforth S; Hanabusa H; Leebeek FW; Lentz SR; Nemes L; Poulsen LH; Santagostino E; You CW; Clausen WH; Jönsson PG; Oldenburg J;
Thromb Haemost; 2017 Jan; 117(2):252-261. PubMed ID: 27904904
[TBL] [Abstract][Full Text] [Related]
18. A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE.
Turecek PL; Romeder-Finger S; Apostol C; Bauer A; Crocker-Buqué A; Burger DA; Schall R; Gritsch H
Haemophilia; 2016 Nov; 22(6):957-965. PubMed ID: 27353010
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of pegylated full-length recombinant factor VIII with extended half-life for perioperative haemostasis in haemophilia A patients.
Brand B; Gruppo R; Wynn TT; Griskevicius L; Lopez Fernandez MF; Chapman M; Dvorak T; Pavlova BG; Abbuehl BE
Haemophilia; 2016 Jul; 22(4):e251-8. PubMed ID: 27328112
[TBL] [Abstract][Full Text] [Related]
20. Parameters influencing FVIII pharmacokinetics in patients with severe and moderate haemophilia A.
Kepa S; Horvath B; Reitter-Pfoertner S; Schemper M; Quehenberger P; Grundbichler M; Heistinger M; Neumeister P; Mannhalter C; Pabinger I
Haemophilia; 2015 May; 21(3):343-350. PubMed ID: 25582282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
